What will be the primary focus of the Gabriella Miller Kids First Research Act 2.0 funding allocation by December 31, 2025?
Genetic research • 25%
Clinical trials • 25%
Data infrastructure • 25%
Other • 25%
Official announcements from the National Institutes of Health or related agencies
Senate Passes $190 Million Pediatric Cancer Research Bill, H.R.3391, After House Approval on March 5, 2024, by 384-4 Vote
Dec 20, 2024, 08:40 PM
A $190 million funding bill for pediatric cancer research, known as the Gabriella Miller Kids First Research Act 2.0, was passed by the Republican-controlled House on March 5, 2024, with an overwhelming vote of 384-4. However, the bill has been stalled in the Democrat-controlled Senate, where Senate Majority Leader Chuck Schumer has not brought it up for a vote. This situation has led to accusations against Democrats for allegedly using the funding as a bargaining chip in broader negotiations. Recently, the Senate passed the bill unanimously, allowing it to move to President Biden for final approval. The bill's passage comes after a period of intense political discourse, where Democrats were criticized for blaming Republicans for the funding's delay, despite the bill's prior approval in the House.
View original story
Majority to existing programs • 25%
Even split between existing and new • 25%
Majority to new initiatives • 25%
Other allocation strategy • 25%
Minimal advancements • 25%
Moderate advancements • 25%
Significant advancements • 25%
No noticeable advancements • 25%
Amended • 25%
Passed • 25%
Rejected • 25%
No Action • 25%
Increase Funding • 25%
No Amendments • 25%
Change Allocation • 25%
Decrease Funding • 25%
Enhanced oversight • 25%
Increased transparency • 25%
No major changes • 25%
Funding restrictions • 25%
Defense • 25%
Healthcare • 25%
Infrastructure • 25%
Disaster Relief • 25%
Yes • 50%
No • 50%
Footprint preservation • 25%
Dinosaur movement • 25%
Dinosaur behavior • 25%
Dinosaur environment • 25%
Opposed • 25%
Supportive • 25%
No Statement • 25%
Neutral • 25%
Other • 25%
Biomarker development • 25%
Gene therapy • 25%
Neuroprotective treatments • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Supportive • 25%
No official stance • 25%
Neutral • 25%
Opposed • 25%